High concordance of findings obtained from transgluteal magnetic resonance imaging ‐ and transrectal ultrasonography‐guided biopsy as compared with prostatectomy specimens

To determine the utility of our transgluteal magnetic resonance imaging (MRI)‐guided prostate biopsy approach.

[1]  H. Samaratunga,et al.  MRI-guided in-bore biopsy for prostate cancer: what does the evidence say? A case series of 554 patients and a review of the current literature , 2018, World Journal of Urology.

[2]  T. Barrett,et al.  Lesion Targeted CT-Guided Transgluteal Prostate Biopsy in Combination With Prebiopsy MRI in Patients Without Rectal Access , 2016, Urology case reports.

[3]  A. Haese*,et al.  Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. , 2016, European urology.

[4]  E. Klein,et al.  CT-Guided Transgluteal Biopsy for Systematic Random Sampling of the Prostate in Patients Without Rectal Access. , 2015, AJR. American journal of roentgenology.

[5]  Nan Zhang,et al.  A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer. , 2015, European urology.

[6]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[7]  Pierre Mozer,et al.  First round of targeted biopsies using magnetic resonance imaging/ultrasonography fusion compared with conventional transrectal ultrasonography‐guided biopsies for the diagnosis of localised prostate cancer , 2015, BJU international.

[8]  P. Asbach,et al.  Die Echtzeit-MRT/US-Fusionsbiopsie in Patienten mit und ohne Vorbiopsie mit Verdacht auf ein Prostatakarzinom , 2014, Aktuelle Urologie.

[9]  David Y. Lu,et al.  Magnetic resonance imaging-ultrasound fusion biopsy for prediction of final prostate pathology. , 2014, The Journal of urology.

[10]  P. Febbo,et al.  A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. , 2014, European urology.

[11]  William L. Welbourn,et al.  Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. , 2014, The Journal of urology.

[12]  F. Schröder,et al.  Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. , 2014, European urology.

[13]  N. Salem,et al.  Comparison of image-guided targeted biopsies versus systematic randomized biopsies in the detection of prostate cancer: a systematic literature review of well-designed studies , 2014, World Journal of Urology.

[14]  Baris Turkbey,et al.  Improving detection of clinically significant prostate cancer: magnetic resonance imaging/transrectal ultrasound fusion guided prostate biopsy. , 2014, The Journal of urology.

[15]  Yejun Qin,et al.  Magnetic resonance imaging‑directed biopsy improves the prediction of prostate cancer aggressiveness compared with a 12‑core transrectal ultrasound‑guided prostate biopsy. , 2014, Molecular medicine reports.

[16]  Shyam Natarajan,et al.  Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen. , 2014, European urology.

[17]  E. Crawford,et al.  Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry , 2014, Current medical research and opinion.

[18]  Anirban P. Mitra,et al.  Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. , 2013, The Journal of urology.

[19]  Baris Turkbey,et al.  Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. , 2013, European urology.

[20]  Anirban P. Mitra,et al.  A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy , 2013, Prostate Cancer and Prostatic Disease.

[21]  Heinz-Peter Schlemmer,et al.  Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer. , 2013, The Journal of urology.

[22]  Xavier Leroy,et al.  Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study. , 2013, Radiology.

[23]  William L. Welbourn,et al.  Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. , 2013, International journal of radiation oncology, biology, physics.

[24]  Anirban P. Mitra,et al.  Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy , 2013, PloS one.

[25]  S. Zangos,et al.  1.5-T Magnetic Resonance–Guided Transgluteal Biopsies of the Prostate in Patients With Clinically Suspected Prostate Cancer: Technique and Feasibility , 2013, Investigative radiology.

[26]  Naira Muradyan,et al.  Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies. , 2013, The Journal of urology.

[27]  Baris Turkbey,et al.  Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. , 2012, The Journal of urology.

[28]  Thomas Hambrock,et al.  Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. , 2012, European urology.

[29]  Hashim Uddin Ahmed,et al.  Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? , 2012, The Lancet. Oncology.

[30]  M. Jordá,et al.  Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols. , 2012, European urology.

[31]  C. Plass,et al.  Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. , 2012, The American journal of pathology.

[32]  J. Verhaegen,et al.  Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy--should we reassess our practices for antibiotic prophylaxis? , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[33]  M. Cooperberg,et al.  Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  D. Schilling,et al.  MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy , 2012, World Journal of Urology.

[35]  Mana Ishibashi,et al.  Detection and Localization of Prostate Cancer With the Targeted Biopsy Strategy Based on ADC Map: A Prospective Large-Scale Cohort Study , 2012, Journal of magnetic resonance imaging : JMRI.

[36]  G. Haber,et al.  Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging‐targeted and systematic biopsy for significant prostate cancer detection , 2011, BJU international.

[37]  Ralph Strecker,et al.  Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding--multiparametric MR imaging for detection and biopsy planning. , 2011, Radiology.

[38]  Ralph Strecker,et al.  Areas Suspicious for Prostate Cancer : MR – guided Biopsy in Patients with at Least One Transrectal US-guided Biopsy with a Negative Finding — Multiparametric MR Imaging for Detection and Biopsy Planning 1 , 2011 .

[39]  Tsuyoshi Mitake,et al.  Real‐time Virtual Sonography for navigation during targeted prostate biopsy using magnetic resonance imaging data , 2010, International journal of urology : official journal of the Japanese Urological Association.

[40]  Thomas Hambrock,et al.  Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. , 2010, The Journal of urology.

[41]  W. Gerald,et al.  Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer , 2010, British Journal of Cancer.

[42]  A P Labanaris,et al.  Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate , 2009, Prostate Cancer and Prostatic Diseases.

[43]  Deanna L Langer,et al.  Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2--sparse versus dense cancers. , 2008, Radiology.

[44]  G. Haas,et al.  The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. , 2008, The Canadian journal of urology.

[45]  Thomas J. Vogl,et al.  MR-compatible assistance system for punction in a high-field system: device and feasibility of transgluteal biopsies of the prostate gland , 2007, European Radiology.

[46]  B. Kiefer,et al.  Prostate biopsy in the supine position in a standard 1.5-T scanner under real time MR-imaging control using a MR-compatible endorectal biopsy device , 2006, European Radiology.

[47]  L. True.  Surgical pathology examination of the prostate gland. Practice survey by American society of clinical pathologists. , 1994, American journal of clinical pathology.

[48]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[49]  C. Catalano,et al.  Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study. , 2015, Urologic oncology.

[50]  P. Asbach,et al.  [Real-time MRI/US fusion-guided biopsy in biopsy-naïve and pre-biopsied patients with suspicion for prostate cancer]. , 2014, Aktuelle Urologie.

[51]  Andrew B Rosenkrantz,et al.  Radiologist, be aware: ten pitfalls that confound the interpretation of multiparametric prostate MRI. , 2014, AJR. American journal of roentgenology.

[52]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[53]  Mark Emberton,et al.  Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. , 2013, European urology.

[54]  Thomas Hambrock,et al.  Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. , 2012, European urology.

[55]  S. Zangos,et al.  MR-guided transgluteal biopsies with an open low-field system in patients with clinically suspected prostate cancer: technique and preliminary results , 2004, European Radiology.

[56]  K. Ahrar,et al.  Various approaches for CT-guided percutaneous biopsy of deep pelvic lesions: anatomic and technical considerations. , 2004, Radiographics : a review publication of the Radiological Society of North America, Inc.

[57]  A. Marx,et al.  World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs , 2004 .

[58]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.